Antiplatelet agents for secondary prevention of stroke

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Patients with recent ischemic stroke or transient ischemic attack (TIA) have a high risk of recurrent vascular events.
• Antiplatelet agents are the preferred antithrombotic drugs for preventing recurrent vascular events when anticoagulation is not indicated.
• Aspirin (ASA) has been the standard first-line therapy for high-risk vascular ischemic events.

Purpose of the Study:

• To evaluate the efficacy of different antiplatelet agents in preventing recurrent vascular events in patients with recent ischemic stroke or TIA.
• To compare the effectiveness of aspirin plus extended-release dipyridamole (ASA/ERDP) and clopidogrel against aspirin alone.

Main Methods:

• Review of two large clinical trials establishing ASA/ERDP superiority over ASA alone.
• Assessment of clopidogrel's efficacy compared to ASA in stroke patients.
• Consideration of the combination of ASA and clopidogrel in stroke patients.

Main Results:

• ASA/ERDP demonstrated superiority over ASA alone in preventing recurrent vascular events in noncardioembolic ischemic stroke or TIA patients.
• Clopidogrel is a viable alternative to ASA, but its superiority in stroke prevention is not definitively established.
• The combination of ASA and clopidogrel has not shown clear benefits or safety in stroke patients, though potential benefits in acute TIA are noted.

Conclusions:

• ASA/ERDP is a highly effective antiplatelet strategy for patients with recent noncardioembolic ischemic stroke or TIA.
• Further research, including upcoming trials comparing ASA/ERDP with clopidogrel, is needed to guide optimal antiplatelet therapy selection.